Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 36 entries
Sorted by: Best Match Show Resources per page
Combined Modality Treatment for Poor Prognosis Stages I and II Hodgkin's Disease.

Seminars in radiation oncology

Cosset JM, Fermé C, Noordijk EM, Dubray BM, Thirion P, Henry-Amar M.
PMID: 10717177
Semin Radiat Oncol. 1996 Jul;6(3):185-195. doi: 10.1053/SRAO00600185.

Recommendations for the treatment of "poor prognosis" stages I and II Hodgkin's disease (HD) depend on the extent of staging. For centers that favor exploratory laparotomy and splenectomy, the standard treatment after negative surgical staging remains subtotal lymphoid irradiation....

Cite
Cosset JM, Fermé C, Noordijk EM, et al. Combined Modality Treatment for Poor Prognosis Stages I and II Hodgkin's Disease. Semin Radiat Oncol. 1996;6(3):185-195doi: 10.1053/SRAO00600185.
Cosset, J. M., Fermé, C., Noordijk, E. M., Dubray, B. M., Thirion, P., & Henry-Amar, M. (1996). Combined Modality Treatment for Poor Prognosis Stages I and II Hodgkin's Disease. Seminars in radiation oncology, 6(3), 185-195. https://doi.org/10.1053/SRAO00600185
Cosset, et al. "Combined Modality Treatment for Poor Prognosis Stages I and II Hodgkin's Disease." Seminars in radiation oncology vol. 6,3 (1996): 185-195. doi: https://doi.org/10.1053/SRAO00600185
Cosset JM, Fermé C, Noordijk EM, Dubray BM, Thirion P, Henry-Amar M. Combined Modality Treatment for Poor Prognosis Stages I and II Hodgkin's Disease. Semin Radiat Oncol. 1996 Jul;6(3):185-195. doi: 10.1053/SRAO00600185. PMID: 10717177.
Copy Download .nbib Format: NLM
Post hoc Analysis of a Randomized, Controlled, Phase 2 Study to Assess Response Rates with Chlormethine/Mechlorethamine Gel in Patients with Stage IA-IIA Mycosis Fungoides.

Dermatology (Basel, Switzerland)

Querfeld C, Scarisbrick JJ, Assaf C, Guenova E, Bagot M, Ortiz-Romero PL, Quaglino P, Bonizzoni E, Hodak E.
PMID: 34091453
Dermatology. 2021 Jun 04;1-11. doi: 10.1159/000516138. Epub 2021 Jun 04.

BACKGROUND: Mycosis fungoides (MF) is the most common form of cutaneous T-cell lymphoma. Patients can be treated using chlormethine gel, a skin-directed therapy developed and approved for MF. In the randomized, controlled 201 trial, chlormethine gel was found to...

Cite
Querfeld C, Scarisbrick JJ, Assaf C, et al. Post hoc Analysis of a Randomized, Controlled, Phase 2 Study to Assess Response Rates with Chlormethine/Mechlorethamine Gel in Patients with Stage IA-IIA Mycosis Fungoides. Dermatology. 2021;1-11doi: 10.1159/000516138.
Querfeld, C., Scarisbrick, J. J., Assaf, C., Guenova, E., Bagot, M., Ortiz-Romero, P. L., Quaglino, P., Bonizzoni, E., & Hodak, E. (2021). Post hoc Analysis of a Randomized, Controlled, Phase 2 Study to Assess Response Rates with Chlormethine/Mechlorethamine Gel in Patients with Stage IA-IIA Mycosis Fungoides. Dermatology (Basel, Switzerland), 1-11. https://doi.org/10.1159/000516138
Querfeld, Christiane, et al. "Post hoc Analysis of a Randomized, Controlled, Phase 2 Study to Assess Response Rates with Chlormethine/Mechlorethamine Gel in Patients with Stage IA-IIA Mycosis Fungoides." Dermatology (Basel, Switzerland) vol. (2021): 1-11. doi: https://doi.org/10.1159/000516138
Querfeld C, Scarisbrick JJ, Assaf C, Guenova E, Bagot M, Ortiz-Romero PL, Quaglino P, Bonizzoni E, Hodak E. Post hoc Analysis of a Randomized, Controlled, Phase 2 Study to Assess Response Rates with Chlormethine/Mechlorethamine Gel in Patients with Stage IA-IIA Mycosis Fungoides. Dermatology. 2021 Jun 04;1-11. doi: 10.1159/000516138. Epub 2021 Jun 04. PMID: 34091453.
Copy Download .nbib Format: NLM
Post hoc Analysis of a Randomized, Controlled, Phase 2 Study to Assess Response Rates with Chlormethine/Mechlorethamine Gel in Patients with Stage IA-IIA Mycosis Fungoides.

Dermatology (Basel, Switzerland)

Querfeld C, Scarisbrick JJ, Assaf C, Guenova E, Bagot M, Ortiz-Romero PL, Quaglino P, Bonizzoni E, Hodak E.
PMID: 34091453
Dermatology. 2021 Jun 04;1-11. doi: 10.1159/000516138. Epub 2021 Jun 04.

BACKGROUND: Mycosis fungoides (MF) is the most common form of cutaneous T-cell lymphoma. Patients can be treated using chlormethine gel, a skin-directed therapy developed and approved for MF. In the randomized, controlled 201 trial, chlormethine gel was found to...

Cite
Querfeld C, Scarisbrick JJ, Assaf C, et al. Post hoc Analysis of a Randomized, Controlled, Phase 2 Study to Assess Response Rates with Chlormethine/Mechlorethamine Gel in Patients with Stage IA-IIA Mycosis Fungoides. Dermatology. 2021;1-11doi: 10.1159/000516138.
Querfeld, C., Scarisbrick, J. J., Assaf, C., Guenova, E., Bagot, M., Ortiz-Romero, P. L., Quaglino, P., Bonizzoni, E., & Hodak, E. (2021). Post hoc Analysis of a Randomized, Controlled, Phase 2 Study to Assess Response Rates with Chlormethine/Mechlorethamine Gel in Patients with Stage IA-IIA Mycosis Fungoides. Dermatology (Basel, Switzerland), 1-11. https://doi.org/10.1159/000516138
Querfeld, Christiane, et al. "Post hoc Analysis of a Randomized, Controlled, Phase 2 Study to Assess Response Rates with Chlormethine/Mechlorethamine Gel in Patients with Stage IA-IIA Mycosis Fungoides." Dermatology (Basel, Switzerland) vol. (2021): 1-11. doi: https://doi.org/10.1159/000516138
Querfeld C, Scarisbrick JJ, Assaf C, Guenova E, Bagot M, Ortiz-Romero PL, Quaglino P, Bonizzoni E, Hodak E. Post hoc Analysis of a Randomized, Controlled, Phase 2 Study to Assess Response Rates with Chlormethine/Mechlorethamine Gel in Patients with Stage IA-IIA Mycosis Fungoides. Dermatology. 2021 Jun 04;1-11. doi: 10.1159/000516138. Epub 2021 Jun 04. PMID: 34091453.
Copy Download .nbib Format: NLM
Second malignancies after autologous haematopoietic stem cell transplantation following modified BEAM conditioning regimen in patients with Hodgkin lymphoma - characteristics and risk factor analysis.

Contemporary oncology (Poznan, Poland)

Czyż A, Lojko-Dankowska A, Matuszak M, Dytfeld D, Kaźmierczak M, Komarnicki M.
PMID: 23788991
Contemp Oncol (Pozn). 2013;17(2):200-4. doi: 10.5114/wo.2013.34626. Epub 2013 Apr 29.

AIM OF THE STUDY: The aim of the study was to determine the incidence of second malignancies among patients with Hodgkin lymphoma (HL) treated with autologous haematopoietic stem cell transplantation (ASCT) following a modified BEAM (BCNU, etoposide, cytarabine, melphalan,...

Cite
Czyż A, Lojko-Dankowska A, Matuszak M, et al. Second malignancies after autologous haematopoietic stem cell transplantation following modified BEAM conditioning regimen in patients with Hodgkin lymphoma - characteristics and risk factor analysis. Contemp Oncol (Pozn). 2013;17(2):200-4doi: 10.5114/wo.2013.34626.
Czyż, A., Lojko-Dankowska, A., Matuszak, M., Dytfeld, D., Kaźmierczak, M., & Komarnicki, M. (2013). Second malignancies after autologous haematopoietic stem cell transplantation following modified BEAM conditioning regimen in patients with Hodgkin lymphoma - characteristics and risk factor analysis. Contemporary oncology (Poznan, Poland), 17(2), 200-4. https://doi.org/10.5114/wo.2013.34626
Czyż, Anna, et al. "Second malignancies after autologous haematopoietic stem cell transplantation following modified BEAM conditioning regimen in patients with Hodgkin lymphoma - characteristics and risk factor analysis." Contemporary oncology (Poznan, Poland) vol. 17,2 (2013): 200-4. doi: https://doi.org/10.5114/wo.2013.34626
Czyż A, Lojko-Dankowska A, Matuszak M, Dytfeld D, Kaźmierczak M, Komarnicki M. Second malignancies after autologous haematopoietic stem cell transplantation following modified BEAM conditioning regimen in patients with Hodgkin lymphoma - characteristics and risk factor analysis. Contemp Oncol (Pozn). 2013;17(2):200-4. doi: 10.5114/wo.2013.34626. Epub 2013 Apr 29. PMID: 23788991; PMCID: PMC3685379.
Copy Download .nbib Format: NLM
Evaluation and management of patients with early-stage mycosis fungoides who interrupt or discontinue topical mechlorethamine gel because of dermatitis.

JAAD case reports

Gilmore ES, Alexander-Savino CV, Chung CG, Poligone B.
PMID: 32904169
JAAD Case Rep. 2020 Jun 03;6(9):878-881. doi: 10.1016/j.jdcr.2020.05.031. eCollection 2020 Sep.

No abstract available.

Cite
Gilmore ES, Alexander-Savino CV, Chung CG, et al. Evaluation and management of patients with early-stage mycosis fungoides who interrupt or discontinue topical mechlorethamine gel because of dermatitis. JAAD Case Rep. 2020;6(9):878-881doi: 10.1016/j.jdcr.2020.05.031.
Gilmore, E. S., Alexander-Savino, C. V., Chung, C. G., & Poligone, B. (2020). Evaluation and management of patients with early-stage mycosis fungoides who interrupt or discontinue topical mechlorethamine gel because of dermatitis. JAAD case reports, 6(9), 878-881. https://doi.org/10.1016/j.jdcr.2020.05.031
Gilmore, Elaine S, et al. "Evaluation and management of patients with early-stage mycosis fungoides who interrupt or discontinue topical mechlorethamine gel because of dermatitis." JAAD case reports vol. 6,9 (2020): 878-881. doi: https://doi.org/10.1016/j.jdcr.2020.05.031
Gilmore ES, Alexander-Savino CV, Chung CG, Poligone B. Evaluation and management of patients with early-stage mycosis fungoides who interrupt or discontinue topical mechlorethamine gel because of dermatitis. JAAD Case Rep. 2020 Jun 03;6(9):878-881. doi: 10.1016/j.jdcr.2020.05.031. eCollection 2020 Sep. PMID: 32904169; PMCID: PMC7452260.
Copy Download .nbib Format: NLM
Reappraisal of the use of procarbazine in the treatment of lymphomas and brain tumors.

Therapeutics and clinical risk management

Armand JP, Ribrag V, Harrousseau JL, Abrey L.
PMID: 18360630
Ther Clin Risk Manag. 2007 Jun;3(2):213-24. doi: 10.2147/tcrm.2007.3.2.213.

Procarbazine HCl is a 'nonclassical' oral alkylating anticancer agent that was first synthesized in the late 1950s. It has been used in the treatment of many cancers, but its main use is in the treatment of Hodgkin's lymphoma and...

Cite
Armand JP, Ribrag V, Harrousseau JL, et al. Reappraisal of the use of procarbazine in the treatment of lymphomas and brain tumors. Ther Clin Risk Manag. 2007;3(2):213-24doi: 10.2147/tcrm.2007.3.2.213.
Armand, J. P., Ribrag, V., Harrousseau, J. L., & Abrey, L. (2007). Reappraisal of the use of procarbazine in the treatment of lymphomas and brain tumors. Therapeutics and clinical risk management, 3(2), 213-24. https://doi.org/10.2147/tcrm.2007.3.2.213
Armand, Jean-Pierre, et al. "Reappraisal of the use of procarbazine in the treatment of lymphomas and brain tumors." Therapeutics and clinical risk management vol. 3,2 (2007): 213-24. doi: https://doi.org/10.2147/tcrm.2007.3.2.213
Armand JP, Ribrag V, Harrousseau JL, Abrey L. Reappraisal of the use of procarbazine in the treatment of lymphomas and brain tumors. Ther Clin Risk Manag. 2007 Jun;3(2):213-24. doi: 10.2147/tcrm.2007.3.2.213. PMID: 18360630; PMCID: PMC1936303.
Copy Download .nbib Format: NLM
Mediastinal choriocarcinoma masquerading as relapsed hodgkin lymphoma.

Case reports in oncology

Lam S, Rizkalla K, Hsia CC.
PMID: 22114578
Case Rep Oncol. 2011 Sep;4(3):512-6. doi: 10.1159/000334080. Epub 2011 Oct 14.

Primary mediastinal choriocarcinoma is a rare extragonadal germ cell malignancy. We describe the first case of a patient who developed mediastinal choriocarcinoma after treatment for Hodgkin lymphoma (HL). A 25-year-old man with classic HL, nodular sclerosis subtype, underwent treatment...

Cite
Lam S, Rizkalla K, Hsia CC. Mediastinal choriocarcinoma masquerading as relapsed hodgkin lymphoma. Case Rep Oncol. 2011;4(3):512-6doi: 10.1159/000334080.
Lam, S., Rizkalla, K., & Hsia, C. C. (2011). Mediastinal choriocarcinoma masquerading as relapsed hodgkin lymphoma. Case reports in oncology, 4(3), 512-6. https://doi.org/10.1159/000334080
Lam, Selay, et al. "Mediastinal choriocarcinoma masquerading as relapsed hodgkin lymphoma." Case reports in oncology vol. 4,3 (2011): 512-6. doi: https://doi.org/10.1159/000334080
Lam S, Rizkalla K, Hsia CC. Mediastinal choriocarcinoma masquerading as relapsed hodgkin lymphoma. Case Rep Oncol. 2011 Sep;4(3):512-6. doi: 10.1159/000334080. Epub 2011 Oct 14. PMID: 22114578; PMCID: PMC3220912.
Copy Download .nbib Format: NLM
Long-term results of the treatment of Hodgkin's lymphoma in a resource-constrained setting: Real-world data from a single center.

World journal of clinical oncology

Sánchez-Valledor LF, Habermann TM, Murrieta-Alvarez I, Córdova-Ramírez AC, Rivera-Álvarez M, León-Peña A, Cantero-Fortiz Y, Olivares-Gazca JC, Ruiz-Delgado GJ, Ruiz-Argüelles GJ.
PMID: 34631443
World J Clin Oncol. 2021 Sep 24;12(9):800-807. doi: 10.5306/wjco.v12.i9.800.

BACKGROUND: The outcomes of Hodgkin´s lymphoma (HL) in México have not been widely reported. Simplified and affordable treatments have been adopted in middle-income countries.AIM: The aim was to evaluate long-used therapies for HL in México in a long-term basis.METHODS:...

Cite
Sánchez-Valledor LF, Habermann TM, Murrieta-Alvarez I, et al. Long-term results of the treatment of Hodgkin's lymphoma in a resource-constrained setting: Real-world data from a single center. World J Clin Oncol. 2021;12(9):800-807doi: 10.5306/wjco.v12.i9.800.
Sánchez-Valledor, L. F., Habermann, T. M., Murrieta-Alvarez, I., Córdova-Ramírez, A. C., Rivera-Álvarez, M., León-Peña, A., Cantero-Fortiz, Y., Olivares-Gazca, J. C., Ruiz-Delgado, G. J., & Ruiz-Argüelles, G. J. (2021). Long-term results of the treatment of Hodgkin's lymphoma in a resource-constrained setting: Real-world data from a single center. World journal of clinical oncology, 12(9), 800-807. https://doi.org/10.5306/wjco.v12.i9.800
Sánchez-Valledor, Luisa Fernanda, et al. "Long-term results of the treatment of Hodgkin's lymphoma in a resource-constrained setting: Real-world data from a single center." World journal of clinical oncology vol. 12,9 (2021): 800-807. doi: https://doi.org/10.5306/wjco.v12.i9.800
Sánchez-Valledor LF, Habermann TM, Murrieta-Alvarez I, Córdova-Ramírez AC, Rivera-Álvarez M, León-Peña A, Cantero-Fortiz Y, Olivares-Gazca JC, Ruiz-Delgado GJ, Ruiz-Argüelles GJ. Long-term results of the treatment of Hodgkin's lymphoma in a resource-constrained setting: Real-world data from a single center. World J Clin Oncol. 2021 Sep 24;12(9):800-807. doi: 10.5306/wjco.v12.i9.800. PMID: 34631443; PMCID: PMC8479346.
Copy Download .nbib Format: NLM
Action of bis(betachloroethyl)sulphide (BCES) on human epidermis reconstituted in culture: Morphological alterations and biochemical depletion of glutathione.

Toxicology in vitro : an international journal published in association with BIBRA

Gentilhomme E, Neveux Y, Hua A, Thiriot C, Faure M, Thivolet J.
PMID: 20732104
Toxicol In Vitro. 1992 Mar;6(2):139-47. doi: 10.1016/0887-2333(92)90007-e.

Human keratinocyte cultures were treated with bis(betachloroethyl)sulphide (BCES), an alkylating and vesicant agent. At concentrations of 5 x 10(-4) to 5 x 10(-3)m, spontaneous detachment of the epithelium from the culture plate was observed, reproducing in vitro the cutaneous...

Cite
Gentilhomme E, Neveux Y, Hua A, et al. Action of bis(betachloroethyl)sulphide (BCES) on human epidermis reconstituted in culture: Morphological alterations and biochemical depletion of glutathione. Toxicol In Vitro. 1992;6(2):139-47doi: 10.1016/0887-2333(92)90007-e.
Gentilhomme, E., Neveux, Y., Hua, A., Thiriot, C., Faure, M., & Thivolet, J. (1992). Action of bis(betachloroethyl)sulphide (BCES) on human epidermis reconstituted in culture: Morphological alterations and biochemical depletion of glutathione. Toxicology in vitro : an international journal published in association with BIBRA, 6(2), 139-47. https://doi.org/10.1016/0887-2333(92)90007-e
Gentilhomme, E, et al. "Action of bis(betachloroethyl)sulphide (BCES) on human epidermis reconstituted in culture: Morphological alterations and biochemical depletion of glutathione." Toxicology in vitro : an international journal published in association with BIBRA vol. 6,2 (1992): 139-47. doi: https://doi.org/10.1016/0887-2333(92)90007-e
Gentilhomme E, Neveux Y, Hua A, Thiriot C, Faure M, Thivolet J. Action of bis(betachloroethyl)sulphide (BCES) on human epidermis reconstituted in culture: Morphological alterations and biochemical depletion of glutathione. Toxicol In Vitro. 1992 Mar;6(2):139-47. doi: 10.1016/0887-2333(92)90007-e. PMID: 20732104.
Copy Download .nbib Format: NLM
Comparative toxicity of sulfur mustard and nitrogen mustard on tracheal epithelial cells in primary culture.

Toxicology in vitro : an international journal published in association with BIBRA

Calvet JH, Feuermann M, Llorente B, Loison F, Harf A, Marano F.
PMID: 20654561
Toxicol In Vitro. 1999 Dec;13(6):859-66. doi: 10.1016/s0887-2333(99)00074-0.

Sulfur mustard (SM) and mechlorethamine (HN2) are two alkylating agents. SM represents a potential chemical warfare agent and HN2 is used in cancer chemotherapy. Based on the similarities of their action, although few comparative studies of their effects have...

Cite
Calvet JH, Feuermann M, Llorente B, et al. Comparative toxicity of sulfur mustard and nitrogen mustard on tracheal epithelial cells in primary culture. Toxicol In Vitro. 1999;13(6):859-66doi: 10.1016/s0887-2333(99)00074-0.
Calvet, J. H., Feuermann, M., Llorente, B., Loison, F., Harf, A., & Marano, F. (1999). Comparative toxicity of sulfur mustard and nitrogen mustard on tracheal epithelial cells in primary culture. Toxicology in vitro : an international journal published in association with BIBRA, 13(6), 859-66. https://doi.org/10.1016/s0887-2333(99)00074-0
Calvet, J H, et al. "Comparative toxicity of sulfur mustard and nitrogen mustard on tracheal epithelial cells in primary culture." Toxicology in vitro : an international journal published in association with BIBRA vol. 13,6 (1999): 859-66. doi: https://doi.org/10.1016/s0887-2333(99)00074-0
Calvet JH, Feuermann M, Llorente B, Loison F, Harf A, Marano F. Comparative toxicity of sulfur mustard and nitrogen mustard on tracheal epithelial cells in primary culture. Toxicol In Vitro. 1999 Dec;13(6):859-66. doi: 10.1016/s0887-2333(99)00074-0. PMID: 20654561.
Copy Download .nbib Format: NLM
The Management of Classical Hodgkin's Lymphoma: Past, Present, and Future.

Advances in hematology

Richardson SE, McNamara C.
PMID: 21687653
Adv Hematol. 2011;2011:865870. doi: 10.1155/2011/865870. Epub 2011 Apr 06.

The management of classical Hodgkin's lymphoma (CHL) is a success story of modern multi-agent haemato-oncology. Prior to the middle of the twentieth century CHL was fatal in the majority of cases. Introduction of single agent radiotherapy (RT) demonstrated for...

Cite
Richardson SE, McNamara C. The Management of Classical Hodgkin's Lymphoma: Past, Present, and Future. Adv Hematol. 2011;2011:865870doi: 10.1155/2011/865870.
Richardson, S. E., & McNamara, C. (2011). The Management of Classical Hodgkin's Lymphoma: Past, Present, and Future. Advances in hematology, 2011865870. https://doi.org/10.1155/2011/865870
Richardson, S E, and McNamara, C. "The Management of Classical Hodgkin's Lymphoma: Past, Present, and Future." Advances in hematology vol. 2011 (2011): 865870. doi: https://doi.org/10.1155/2011/865870
Richardson SE, McNamara C. The Management of Classical Hodgkin's Lymphoma: Past, Present, and Future. Adv Hematol. 2011;2011:865870. doi: 10.1155/2011/865870. Epub 2011 Apr 06. PMID: 21687653; PMCID: PMC3112512.
Copy Download .nbib Format: NLM
Chlormethine Gel for the Treatment of Skin Lesions in All Stages of Mycosis Fungoides Cutaneous T-Cell Lymphoma: A Narrative Review and International Experience.

Dermatology and therapy

Geskin LJ, Bagot M, Hodak E, Kim EJ.
PMID: 34021485
Dermatol Ther (Heidelb). 2021 Aug;11(4):1085-1106. doi: 10.1007/s13555-021-00539-3. Epub 2021 May 21.

Mycosis fungoides (MF), the most common form of primary cutaneous T-cell lymphoma, is a disease typically with an indolent course that is initially characterized by localized patches and plaques. In the early stages of the disease, treatment involves skin-directed...

Cite
Geskin LJ, Bagot M, Hodak E, et al. Chlormethine Gel for the Treatment of Skin Lesions in All Stages of Mycosis Fungoides Cutaneous T-Cell Lymphoma: A Narrative Review and International Experience. Dermatol Ther (Heidelb). 2021;11(4):1085-1106doi: 10.1007/s13555-021-00539-3.
Geskin, L. J., Bagot, M., Hodak, E., & Kim, E. J. (2021). Chlormethine Gel for the Treatment of Skin Lesions in All Stages of Mycosis Fungoides Cutaneous T-Cell Lymphoma: A Narrative Review and International Experience. Dermatology and therapy, 11(4), 1085-1106. https://doi.org/10.1007/s13555-021-00539-3
Geskin, Larisa J, et al. "Chlormethine Gel for the Treatment of Skin Lesions in All Stages of Mycosis Fungoides Cutaneous T-Cell Lymphoma: A Narrative Review and International Experience." Dermatology and therapy vol. 11,4 (2021): 1085-1106. doi: https://doi.org/10.1007/s13555-021-00539-3
Geskin LJ, Bagot M, Hodak E, Kim EJ. Chlormethine Gel for the Treatment of Skin Lesions in All Stages of Mycosis Fungoides Cutaneous T-Cell Lymphoma: A Narrative Review and International Experience. Dermatol Ther (Heidelb). 2021 Aug;11(4):1085-1106. doi: 10.1007/s13555-021-00539-3. Epub 2021 May 21. PMID: 34021485; PMCID: PMC8322195.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 36 entries